Forte Biosciences, Inc. $(FBRX)$, a clinical-stage biopharmaceutical company, has announced the presentation of results from its FB102 Celiac Disease Trial at the Tampere Celiac Disease Symposium in Finland. The oral presentation highlighted the outcomes of a phase 1b study which demonstrated that FB102 effectively prevents histological damage and mitigates gluten challenge-induced symptoms in patients with celiac disease. Key findings included a significant decline in TCR γδ density in patients treated with FB102 compared to those on placebo, as well as a reduction in Ki67-positive intraepithelial cell density and a 95% decline in NK cells. These results suggest that FB102 may offer a differentiated therapeutic option for celiac disease. The phase 2 trial is currently underway, with topline data anticipated in 2026.